Effects of drospirenone/estrogen combinations on bone metabolism

  title={Effects of drospirenone/estrogen combinations on bone metabolism},
  author={Claus Christiansen},
  pages={35 - 41}
Bone mass is maintained when low-dose ethinylestradiol is used in combination with the new progestogen drospirenone as an oral contraceptive, making a regimen of drospirenone combined with 17β-estradiol an attractive option for hormone replacement therapy (HRT) in postmenopausal women. Drospirenone is a novel progestogen, more closely related to endogenous progesterone in its pharmacological properties than other progestogens available; in combination with estrogen, drospirenone can closely… 


NETA have beneficial effects on both lipid and carbohydrate metabolism in postmenopausal women and under the light of these data it is wise to suggest NETA containing low dose hormone therapy preparations in post menopausal women with diabetes risk for controlling vasomotor complaints.

Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms

  • O. Ylikorkala
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2005
A novel progestin is introduced, drospirenone, to be used in combination with ethinylestradiol for oral contraception or with estradiol with potentially harmful side-effects which are potentially harmful and reduce the tolerability of the contraceptive pill or HT.

Long-term effects of progestins on bone quality and fractures

  • J. Thijssen
  • Medicine, Biology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
In postmenopausal women, no evidence has been found for a bone-protective or an estrogen-antagonistic effect of progestin, and a wide range of estrogens have been used that have shown positive effects on bone, which are not antagonized by progestins.

Effect of a mixture of calcium, vitamin D, inulin and soy isoflavones on bone metabolism in post-menopausal women: a retrospective analysis

These results suggest that the considered mixture improved intestinal calcium absorption and bone metabolism in post-menopausal women.

Estrogen counteracts ozone-induced oxidative stress and nigral neuronal death

Results indicate that ozone exposure may be a useful Parkinson's disease model and neuroprotection afforded by 17&bgr;-estradiol is dependent on the high levels achieved after its prolonged administration.

Telbivudine (Tyzeka) for Chronic Hepatitis B

  • Biology, Chemistry
    The Medical letter on drugs and therapeutics
  • 2007
Chronic HBV infection is currently treated with weekly injections of pegylated interferon alfa (Pegasys), or oncedaily oral treatment with a nucleoside analog such as lamivudine or entecavir or the nucleotide analog adefovir.

17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period

Okres „po WHI” (Women’s Health Inititive), czyli czas swoistego odwrotu od terapii hormonalnej okresu menopauzy (menopausal hormone therapy – MHT), z jednej strony skupił jak w pigułce wszystkie



Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis

Although endometrial thickness increased slightly, the safety of the endometrium was assured, as no cases of hyperplasia or cancer occurred, and the combination of 17β-estradiol and drospirenone has a positive effect on BMD and a potentially beneficial effect on lipids.

Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.

  • A. Rübig
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2003
Phase III studies with E2/DRSP show that DRSP does not antagonize the well-documented reductions of blood pressure associated with E1; rather, small DRSP dose-related reductions in systolic and diastolic blood pressures were observed, which should be beneficial for recipients, especially those who are mildly hypertensive.

Pharmacology of estradiol valerate/dienogest.

  • A. Teichmann
  • Biology, Medicine
    Climacteric : the journal of the International Menopause Society
  • 2003
E2V/DNG is well suited as an effective hormone replacement therapy, with the potential for good bleeding patterns and low androgenicity, owing to its formulation with a progestogenic component that is highly endometriotropic, has low antiestrogenicity and exhibits considerable antiandrogenicity.

Effect of Continuous Combined Estrogen and Desogestrel Hormone Replacement Therapy on Serum Lipids and Lipoproteins

The results indicate that when desogestrel 0.15 mg/day is combined with micronized 17β-E2 1mg/day in a continuous manner, the effects of the progestogen on HDL predominate and cause a reduction in HDL and the HDL2 subtraction.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial

Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.

Early postmenopausal hormone therapy may prevent cognitive impairment later in life

The results of the present study suggest that previous short-term HT administered in the early phase of the menopause may provide a long-term protection against cognitive impairment.